Ankylosing Spondylitis Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, ROA, MOA and Companies involved by DelveInsight | Pfizer, UCB Biopharma, Fresenius Kabi, Shanghai Henlius

(Albany, United States) As per DelveInsight's assessment, globally, Ankylosing Spondylitis pipeline constitutes 20+ key companies continuously working towards developing 20+ Ankylosing Spondylitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Ankylosing Spondylitis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ankylosing Spondylitis Market.
The Ankylosing Spondylitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details

Request for sample report @ https://www.delveinsight.com/report-store/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Ankylosing Spondylitis Pipeline Report:
• Ankylosing Spondylitis Companies across the globe are diligently working toward developing novel Ankylosing Spondylitis treatment therapies with a considerable amount of success over the years.
• Ankylosing Spondylitis companies working in the treatment market are Kinevant Sciences, MoonLake Immunotherapeutics, Qyuns Therapeutics, Suzhou Zelgen Biopharmaceuticals, Jiangsu HengRui MedicIne, Suzhou Zelgen Biopharmaceuticals, Amgen, and others, are developing therapies for the Ankylosing Spondylitis treatment
• Emerging Ankylosing Spondylitis therapies in the different phases of clinical trials are- KIN-1901, Sonelokimab, QX 002N, SHR-1314, SHR0302, Jaktinib, Apremilast, and others are expected to have a significant impact on the Ankylosing Spondylitis market in the coming years.
• UCB Biopharma: On November 14, 2024, UCB Biopharma presented new two-year data for Bimekizumab (bimekizumab-bkzx) at the American College of Rheumatology (ACR) Convergence 2024, showing sustained improvements in clinical and patient-reported outcomes for Ankylosing Spondylitis.
• MoonLake Immunotherapeutics: MoonLake Immunotherapeutics is actively working on Phase 3 clinical trials for their lead candidate, belimumab, with updates reported as of April 2024.
• Qyuns Therapeutics: Qyuns Therapeutics is involved in the development of novel small molecule inhibitors for Ankylosing Spondylitis, with updates reported as of April 2024.
• Suzhou Zelgen Biopharmaceuticals: Suzhou Zelgen Biopharmaceuticals continues to work on Axial Spondyloarthritis treatments, with updates reported as of April 2024.
• Jiangsu HengRui MedicIne: Jiangsu HengRui MedicIne is developing new therapeutic options for Ankylosing Spondylitis, with updates reported as of April 2024.
• In October 2023, RINVOQ by AbbVie is prescribed for adults with active ankylosing spondylitis who have not responded satisfactorily to conventional therapy.
• In October 2023, In the European Union, bimekizumab has received approval for addressing moderate to severe plaque psoriasis in adults eligible for systemic therapy. It is also approved for treating active psoriatic arthritis and active axSpA in adults, encompassing both non-radiographic axSpA and ankylosing spondylitis, also recognized as radiographic axSpA. Note that labeling information may vary in other approved regions, and it is advisable to refer to local prescribing guidelines. It is crucial to highlight that the efficacy and safety of bimekizumab in HS (Hidradenitis Suppurativa) have not been validated, and regulatory authorities worldwide have not granted approval for its use in this indication.

Ankylosing Spondylitis Overview
Ankylosing Spondylitis is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, leading to pain and stiffness. It is a type of axial spondyloarthritis and an autoimmune condition where the body's immune system attacks its tissues, causing inflammation. Over time, this inflammation can lead to the fusion of vertebrae, significantly reducing flexibility and mobility. In severe cases, the spine can become rigid, a condition called "bamboo spine."
Ankylosing Spondylitis commonly begins in early adulthood, with symptoms like lower back pain, morning stiffness, and fatigue. These symptoms often improve with activity and worsen with rest. While the exact cause of AS is unknown, a strong genetic link exists, particularly with the HLA-B27 gene. It can also affect other areas, such as the hips, shoulders, and even organs like the eyes, causing uveitis.
Treatment focuses on managing symptoms and preventing complications. Nonsteroidal anti-inflammatory drugs (NSAIDs), biologics like TNF or IL-17 inhibitors, and physical therapy are commonly used. Early diagnosis and consistent management are key to improving quality of life and maintaining mobility. Ankylosing Spondylitis is lifelong but can be effectively managed with a comprehensive care approach.

Get a Free Sample PDF Report to know more about Ankylosing Spondylitis Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Ankylosing Spondylitis Drugs Under Different Phases of Clinical Development Include:
• KIN-1901: Kinevant Sciences
• Sonelokimab: MoonLake Immunotherapeutics
• QX 002N: Qyuns Therapeutics
• SHR-1314: Suzhou Zelgen Biopharmaceuticals
• SHR0302: Jiangsu HengRui MedicIne
• Jaktinib: Suzhou Zelgen Biopharmaceuticals
• Apremilast: Amgen

Ankylosing Spondylitis Route of Administration
Ankylosing Spondylitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Topical.

Ankylosing Spondylitis Molecule Type
Ankylosing Spondylitis Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Ankylosing Spondylitis Pipeline Therapeutics Assessment
• Ankylosing Spondylitis Assessment by Product Type
• Ankylosing Spondylitis By Stage and Product Type
• Ankylosing Spondylitis Assessment by Route of Administration
• Ankylosing Spondylitis By Stage and Route of Administration
• Ankylosing Spondylitis Assessment by Molecule Type
• Ankylosing Spondylitis by Stage and Molecule Type

DelveInsight's Ankylosing Spondylitis Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Ankylosing Spondylitis product details are provided in the report. Download the Ankylosing Spondylitis pipeline report to learn more about the emerging Ankylosing Spondylitis therapies - https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Ankylosing Spondylitis Therapeutics Market include:
Key companies developing therapies for Ankylosing Spondylitis are - Pfizer, UCB Biopharma, Fresenius Kabi, Shanghai Henlius Biotech, Fujifilm Kyowa Kirin Biologics, Hetero Biopharma, Bio-Thera Solutions, Amgen, CinnaGen, Zydus cadilla, Cadila Pharmaceuticals, Sandoz, Innovent Biologics, Torrent Pharmaceuticals, Cipla, Emcure Pharmaceuticals, Biogen, Boehringer Ingelheim, Zhejiang Hisun Pharmaceuticals, Biocad, AbbVie, Mycenax Biotech, Celltrion, Gilead Sciences, Amgen, Sun Pharma Global, Jiangsu HengRui Medicine Co., Ltd., Izana Bioscience, Suzhou Zelgen Biopharmaceuticals, Iltoo Pharma, Kinevant Sciences, Qyuns Therapeutics, Akeso Biopharma, Nimbus Therapeutics, Enzene Biosciences, Xbrane Biopharma, Dice molecules, and others.

Ankylosing Spondylitis Pipeline Analysis:
The Ankylosing Spondylitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Ankylosing Spondylitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ankylosing Spondylitis Treatment.
• Ankylosing Spondylitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Ankylosing Spondylitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ankylosing Spondylitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Ankylosing Spondylitis drugs and therapies - https://www.delveinsight.com/report-store/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Ankylosing Spondylitis Pipeline Market Drivers
Rising prevalence of ankylosing spondylitis, increase in Drug Development for Ankylosing spondylitis are some of the important factors that are fueling the Ankylosing Spondylitis Market.

Ankylosing Spondylitis Pipeline Market Barriers
However, lack of early diagnosis of the disease, minimum participation of patients in physical activity
High treatment cost and lack of caregiver and other factors are creating obstacles in the Ankylosing Spondylitis Market growth.

Scope of Ankylosing Spondylitis Pipeline Drug Insight
• Coverage: Global
• Key Ankylosing Spondylitis Companies: Kinevant Sciences, MoonLake Immunotherapeutics, Qyuns Therapeutics, Suzhou Zelgen Biopharmaceuticals, Jiangsu HengRui MedicIne, Suzhou Zelgen Biopharmaceuticals, Amgen, and others
• Key Ankylosing Spondylitis Therapies: KIN-1901, Sonelokimab, QX 002N, SHR-1314, SHR0302, Jaktinib, Apremilast, and others
• Ankylosing Spondylitis Therapeutic Assessment: Ankylosing Spondylitis current marketed and Ankylosing Spondylitis emerging therapies
• Ankylosing Spondylitis Market Dynamics: Ankylosing Spondylitis market drivers and Ankylosing Spondylitis market barriers

Request for Sample PDF Report for Ankylosing Spondylitis Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/ankylosing-spondylitis-bekhterevs-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Ankylosing Spondylitis Report Introduction
2. Ankylosing Spondylitis Executive Summary
3. Ankylosing Spondylitis Overview
4. Ankylosing Spondylitis- Analytical Perspective In-depth Commercial Assessment
5. Ankylosing Spondylitis Pipeline Therapeutics
6. Ankylosing Spondylitis Late Stage Products (Phase II/III)
7. Ankylosing Spondylitis Mid Stage Products (Phase II)
8. Ankylosing Spondylitis Early Stage Products (Phase I)
9. Ankylosing Spondylitis Preclinical Stage Products
10. Ankylosing Spondylitis Therapeutics Assessment
11. Ankylosing Spondylitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Ankylosing Spondylitis Key Companies
14. Ankylosing Spondylitis Key Products
15. Ankylosing Spondylitis Unmet Needs
16 . Ankylosing Spondylitis Market Drivers and Barriers
17. Ankylosing Spondylitis Future Perspectives and Conclusion
18. Ankylosing Spondylitis Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Calcinosis Cutis Market: https://www.delveinsight.com/report-store/calcinosis-cutis-market
• Aicardi-goutières Syndrome Market: https://www.delveinsight.com/report-store/aicardi-goutieres-syndrome-market
• Cellulitis Market: https://www.delveinsight.com/report-store/cellulitis-epidemiology-forecast
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Hemophilia With Inhibitor Market: https://www.delveinsight.com/report-store/hemophilia-a2030-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Hemodynamic Monitoring Systems Market: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market
• Chronic Gout Market: https://www.delveinsight.com/report-store/chronic-gout-market
• Myocardial Infarction Market: https://www.delveinsight.com/report-store/myocardial-infarction-market
• Critical Limb Ischemia Market: https://www.delveinsight.com/report-store/critical-limb-ischemia-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Precocious Puberty Market: https://www.delveinsight.com/report-store/precocious-puberty-market
• Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market
• Beta Thalassemia Market: https://www.delveinsight.com/report-store/beta-thalassemia-market
• Chronic Refractory Cough Market: https://www.delveinsight.com/report-store/chronic-refractory-cough-market
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Eosinophilic Asthma Market: https://www.delveinsight.com/report-store/eosinophilic-asthma-market
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/sample-request/familial-primary-pulmonary-hypertension-market
• Trigeminal Neuralgia Market Size: https://www.delveinsight.com/report-store/trigeminal-neuralgia-market
• Walking Impairment In Multiple Sclerosis Market: https://www.delveinsight.com/report-store/walking-impairment-in-multiple-sclerosis-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Actinic Keratosis Market: https://www.delveinsight.com/report-store/actinic-keratosis-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiac Restoration Systems Market: https://www.delveinsight.com/report-store/cardiac-restoration-systems-market
• Central Pain Syndrome Market: https://www.delveinsight.com/report-store/central-pain-syndrome-market
• Corneal Ulcer Market: https://www.delveinsight.com/report-store/corneal-ulcer-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/primary-research-services
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.